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Effective management of heart failure is complex, and ensuring evidence-based practice
presents a major challenge to health services worldwide. Over the past decade, the United
Kingdom introduced a series of national initiatives to improve evidence-based heart failure
management, including a landmark pay-for-performance scheme in primary care and a
national audit in secondary care started in 2004 and 2007, respectively. Quality improve-
ment efforts have been evaluated within individual clinical settings, but patterns of care
across its continuum, although a critical component of chronic disease management, have
not been studied. We have designed this study to investigate patients’ trajectories of care
around the time of diagnosis and their variation over time by age, sex, and socioeconomic
status.
Methods and findings
For this retrospective population-based study, we used linked primary and secondary health
records from a representative sample of the UK population provided by the Clinical Practice
Research Datalink (CPRD). We identified 93,074 individuals newly diagnosed with heart
failure between 2002 and 2014, with a mean age of 76.7 years and of which 49% were
women. We examined five indicators of care: (i) diagnosis care setting (inpatient or
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outpatient), (ii) posthospitalisation follow-up in primary care, (iii) diagnostic investigations,
(iv) prescription of essential drugs, and (v) drug treatment dose. We used Poisson and linear
regression models to calculate category-specific risk ratios (RRs) or adjusted differences
and 95% confidence intervals (CIs), adjusting for year of diagnosis, age, sex, region, and
socioeconomic status. From 2002 to 2014, indicators of care presented diverging trends.
Outpatient diagnoses and follow-up after hospital discharge in primary care declined sub-
stantially (ranging from 56% in 2002 to 36% in 2014, RR 0.64 [0.62, 0.67] and 20% to 14%,
RR 0.73 [0.65, 0.82], respectively). Primary care referral for diagnostic investigations and
appropriate initiation of beta blockers and angiotensin-converting–enzyme inhibitors (ACE-
Is) or angiotensin receptor blockers (ARBs) both increased significantly (37% versus 82%,
RR 2.24 [2.15, 2.34] and 18% versus 63%, RR 3.48 [2.72, 4.43], respectively). Yet, the aver-
age daily dose prescribed remained below guideline recommendations (42% for ACE-Is or
ARBs, 29% for beta blockers in 2014) and was largely unchanged beyond the first 30 days
after diagnosis. Despite increasing rates of treatment initiation, the overall dose prescribed
to patients in the 12 months following diagnosis improved little over the period of study
(adjusted difference for the combined dose of beta blocker and ACE-I or ARB: +6% [+2%,
+10%]). Women and patients aged over 75 years presented significant gaps across all five
indicators of care. Our study was limited by the available clinical information, which did not
include exact left ventricular ejection fraction values, investigations performed during hospi-
tal admissions, or information about follow-up in community heart failure clinics.
Conclusions
Management of heart failure patients in the UK presents important shortcomings that affect
screening, continuity of care, and medication titration and disproportionally impact women
and older people. National reporting and incentive schemes confined to individual clinical
settings have been insufficient to identify these gaps and address patients’ long-term care
needs.
Author summary
Why was this study done?
• Heart failure is a common, costly, and severe condition—it affects about 2% of the pop-
ulation in high-income countries, with mortality rates comparable to the gravest forms
of cancer.
• Effective treatments exist but involve a complex process of investigations, stepwise initi-
ation of medicines, and dose adjustments that in practice is often challenging to follow.
• Over the past decade, the UK introduced separate programmes to evaluate and improve
the management of heart failure patients in primary and secondary care. However,
patients’ trajectories of care across different healthcare settings have not been studied.
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What did the researchers do and find?
• We aimed to investigate the medical care received by heart failure patients in the UK
from diagnosis up to a year later.
• We used electronic health records from 93,000 patients who were diagnosed with heart
failure between 2002 and 2014. We investigated trajectories of care, including where
patients were diagnosed, investigations that were performed, and medications they
received, examined changes over time and if results differed according to patients’ age,
sex, or socioeconomic status.
• Our results show that the medical care received by heart failure patients presents impor-
tant gaps. Patients were more likely to be diagnosed in hospital rather than by their gen-
eral practitioner, received insufficient follow-up after hospitalisation, and dosages
prescribed to patients were too low. Moreover, gaps in care were more common in
women, older people, and, to some extent, socioeconomically deprived individuals.
What do these findings mean?
• Heart failure care in the UK presents important gaps that pertain to patients’ long-term
care needs and are likely to negatively impact patients’ health and quality of life.
• Nationwide quality improvement programmes have failed to identify these gaps, essen-
tially because they evaluate each individual healthcare setting on its own. To further
improve patient care, health systems may need to reflect on patients’ journey across the
continuum of care.
• Women, older people, and deprived populations are particularly prone to receiving sub-
optimal care. Research that helps us understand the reasons behind these disparities, or
models of care that take each group’s specificities into account, could help.
Introduction
Over the past 25 years, we have witnessed remarkable developments in clinical interventions
that improve symptoms, quality of life, and prognosis in patients with heart failure. However,
effective clinical care involves a complex process of investigations, stepwise initiation of medi-
cines, and dose titration that often takes place in different care settings over several months
and can be difficult to implement consistently. Although clinical guidelines provide a valuable
tool to support physicians in the management of heart failure patients [1–7], ensuring optimal
use of evidence-based therapies in routine clinical practice remains a major concern and chal-
lenge to health services worldwide [8,9].
In the UK, two major programmes have been introduced to improve physicians’ adherence
to evidence-based practices: the ‘Quality and Outcomes Framework’ (QOF) [10], a healthcare
reporting and incentive scheme that applies to primary care physicians and was initiated in
2004; and the ‘National Heart Failure Audit’ (NHFA) [11], a large-scale reporting scheme for
secondary care launched in 2007. Each scheme individually produces yearly reports on
selected heart failure care indicators with very high rates of adherence to clinical guidelines
Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure
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[12,13]. Yet, programmes only consider the clinical setting for which they were designed and
have not assessed their broader impact on patient care across the continuum of primary and
secondary services, which chronic conditions, such as heart failure, rely on. More generally,
similar limitations apply to studies that have investigated heart failure care in Western coun-
tries. So far, studies have been largely confined to specific clinical settings, selected cohorts,
and limited follow-up information, with no ability to describe and compare patient trajectories
following a new diagnosis of heart failure (S1 Table). Finally, little is known of variations in
care practices by important patient characteristics, such as age or sex.
To address these knowledge gaps, we used a database of linked primary and secondary
healthcare records in the UK [14] and performed a longitudinal assessment of outpatient care,
covering diagnosis, follow-up, diagnostic investigations, treatment initiation, and dosages in
patients with incident heart failure. We further sought to investigate temporal trends and vari-
ation by important patient characteristics such as age, sex, and socioeconomic status.
Methods
Data source
We used electronic health records from the Clinical Practice Research Datalink (CPRD) from
1 January 1985 to 30 September 2015. The CPRD database contains anonymised patient data
from approximately 7% of the current UK population and is broadly representative in terms of
age and sex. CPRD is one of the largest databases of longitudinal medical records from primary
care in the world and has been validated for epidemiological research for a broad range of con-
ditions [14]. Primary care records include demographic information, consultations, drug pre-
scriptions, diagnostic investigations, and referrals to specialists and were linked to secondary
care admission records from Hospital Episodes Statistics (HES), which provides information
on hospital admissions and related discharge diagnoses. Scientific approval for this study was
given by the CPRD Independent Scientific Advisory Committee (ISAC).
Study population
Patients were men and women aged 16 and over, with records labelled as ‘acceptable’ for
research purposes by CPRD quality control [14], approved for CPRD and HES linkage, and
registered with their general practice for at least 12 months. Amongst these 4.0 million
patients, we identified 93,074 with incident heart failure during the period 1 January 2002 to
31 December 2014. Incident heart failure diagnoses were defined as the first record of heart
failure in primary care or hospital admission recorded in any diagnostic position and were
identified following previously published methods [15].
Study outcomes
We examined five aspects of care across the disease trajectory of patients with heart failure: (i)
diagnosis care setting, (ii) posthospitalisation follow-up, (iii) diagnostic investigations, (iv) pre-
scription of essential medicines, and (v) treatment dosages. Data about diagnostic investiga-
tions and prescriptions were only available in primary care records, so indicators (iii), (iv), and
(v) were restricted to patients whose heart failure was recorded in primary care (n = 47,925).
Analysis of guideline-recommended drug treatment was further restricted to patients with
reduced ejection fraction (n = 11,040) with no record of drug-class–specific contraindications
or intolerance (S2 and S3 Tables). Fig 1 provides an overview of study outcome measures,
with further details provided below.
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The care setting in which heart failure was first diagnosed was categorised as either inpa-
tient or outpatient. Inpatient diagnoses were further categorised based on whether heart failure
was listed in primary or secondary diagnostic position. Outpatient diagnoses refer to diagnoses
first recorded in primary care with no prior hospitalisation and are likely to reflect both outpa-
tient consultations by specialists and direct diagnoses by general practitioners.
The potential for primary care follow-up after diagnosis in hospital (in short follow-up) was
defined as the documentation of heart failure in primary care records within 12 months of
diagnosis, with the rationale that documentation of diagnosis is a prerequisite for subsequent
disease monitoring and management (S1 Text).
Diagnostic investigations included tests recommended as “essential” by the European Soci-
ety of Cardiology (ESC) guidelines [6]: (i) echocardiogram, (ii) electrocardiogram (ECG), and
(iii) plasma natriuretic peptides (B-type natriuretic peptide [BNP] or N-terminal-pro-BNP
[NT-pro-BNP]), as well as (iv) cardiology specialist assessment, within ±6 months of incident
heart failure diagnosis. Diagnostic tests were considered individually and as a composite of
any of the four tests. The list of diagnostic codes used to identify diagnostic tests is presented
in S4 Table.
Drug treatment patterns were investigated for the three main treatment classes indicated in
the management of heart failure with reduced ejection fraction by the ESC guidelines [6]: (i)
angiotensin-converting-enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs),
(ii) beta blockers, and (iii) mineralocorticoid receptor antagonists (MRAs).
For each of the three drug classes, we report treatment initiation as the proportion of eligi-
ble patients who received at least one prescription in the first three months following their
Fig 1. Definitions of essential care indicators. ACE-I, angiotensin-converting–enzyme inhibitor; ARB, angiotensin receptor blocker; ECG, electrocardiogram; MRA,
mineralocorticoid receptor antagonist; NP, natriuretic peptide.
https://doi.org/10.1371/journal.pmed.1002805.g001
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heart failure diagnosis. We defined a composite treatment initiation indicator as prescriptions
for the two treatment classes indicated in all patients with heart failure with reduced ejection
fraction, which are ACE-Is or ARBs and beta blockers.
We further calculated the average daily dose prescribed to eligible patients over all days
alive and registered with their general practice in the first 12 months following incident heart
failure (S2 Text). We present average daily doses as a fraction of the drug-specific guideline-
recommended dose. Daily doses were calculated for all eligible patients, irrespective of receipt
of treatment, as an estimate of population level of treatment. The guideline-recommended
doses were defined as the minimal target dose recommended by the latest ESC guidelines
available during the study period (S5 Table). Average daily dose was analysed as a continuous
variable, as a binary variable (<50% or�50% of recommended dose), as well as categorised
into 0%, 1%–24%, 25%–49%, 50%–74%, and�75% of the recommended dose. Because drugs
used for treatment of heart failure are also used for other indications, we further investigated
average daily dose prescribed in the 3 months preceding diagnosis.
Patient characteristics
We extracted the most recent measurement of baseline characteristics within two years pre-
ceding incident heart failure diagnosis including systolic and diastolic blood pressure, smoking
status, and body-mass index (BMI). BMI was categorised as underweight (<18.5 kg/m2), nor-
mal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese (�30 kg/m2).
We further extracted information on comorbidities and socioeconomic status. To describe
comorbidities, we selected 17 common chronic conditions (anaemia, asthma, atrial fibrillation,
cancer, chronic kidney disease, chronic obstructive pulmonary disease, dementia, depression,
diabetes, dyslipidaemia, hypertension, ischaemic heart disease, obesity, osteoarthritis, periph-
eral arterial disease, stroke, and thyroid disease). Diagnosis code lists for the extraction of each
condition were adapted from the CALIBER code repository [16]. To describe socioeconomic
status, we used patients’ Index of Multiple Deprivation (IMD) 2015 quintile [17], a composite
measure of relative deprivation at a small area level, ranked in ascending order of deprivation
score and grouped in equal fifths.
Statistical analyses
For binary or categorical outcome variables, we computed age, sex, socioeconomic, and year-
specific risks as the proportion of eligible patients who received care within a defined time-
frame of incident heart failure diagnosis. To assist readability, we further refer to risks, propor-
tions, and rates interchangeably. For continuous outcome variables, we computed means and
standard deviations.
To examine changes over time and by subgroups, we used Poisson or linear regression
models with robust error variance and report risk ratios (RRs) or adjusted mean differences
alongside corresponding 95% confidence intervals (CIs). All models were adjusted for year of
diagnosis, age (categorised as<45, 45–54, 55–64, 65–74, and�75 years), sex, region, and
socioeconomic status. As a measure of temporal trend, we further report p-values modelled by
including year as a continuous variable. Selected graphical representations were smoothed
using local polynomial regression and labelled as such in the figure caption [18,19].
We performed several sensitivity analyses to assess the robustness of our results towards dif-
ferences in follow-up duration, 30-day mortality, or prevalence of comorbidities over time and
by subgroups (S3 Text).
Study findings are reported in accordance with the REporting of studies Conducted using
Observational Routinely collected health Data (RECORD) recommendations (S4 Text) [20].
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Analyses were prospectively specified in the study protocol (S5 Text), and all statistical analy-
ses were performed in R, version 3.4.2 (R Foundation for Statistical Computing, Vienna,
Austria).
Results
A total of 93,074 patients newly diagnosed with heart failure between 2002 and 2014 were
included in the study. Patient characteristics stratified by sex, socioeconomic status, and time
period categories have been previously published [15]. Patient characteristics varied depending
on where they were first diagnosed; those diagnosed in hospital were older, had more comor-
bidities, and were more likely to be women (Table 1). Patients with a record of reduced ejec-
tion fraction were more likely to be younger, be male, and present with fewer comorbidities
than those for whom ejection fraction was preserved or unspecified (S6 Table).
Temporal trends of essential care indicators
Setting of heart failure diagnosis. Between 2002 and 2014, a diagnosis of heart failure
was first recorded during a hospitalisation in 56% of cases (12% as a primary diagnosis and
44% as a secondary diagnosis) and in an outpatient setting in 44% (Table 2). Amongst second-
ary inpatient diagnoses of heart failure, about a third of primary causes for admission were car-
diac and a fifth were respiratory disease.
Whilst the proportion of patients diagnosed in hospital with primary heart failure diagnosis
remained stable at 12%, there were opposing trends for secondary inpatient diagnoses versus
outpatient diagnoses. Rates of outpatient diagnoses showed a 36% relative decline over time
(from 56% in 2002 to 36% in 2014, RR 0.64 [0.62, 0.67]) and were offset by a 67% relative
increase in secondary inpatient diagnoses (from 31% in 2002 to 52% in 2014, RR 1.67 [1.60,
1.74]) (Table 2).
Primary care follow-up after hospitalisation. Amongst heart failure inpatients who sur-
vived the index hospitalisation, only 17% had their heart failure diagnosis recorded by their
primary care physician in the subsequent 12 months, with rates declining over time (20% in
2002 versus 14% in 2014; RR 0.73 [0.65, 0.82]) (Fig 2). Follow-up rates were higher for patients
with a primary discharge diagnosis of heart failure (31%) than secondary diagnosis (12%)
(Table 2).
Diagnostic tests. Amongst patients with a recorded diagnosis of heart failure in primary
care, the use of diagnostic investigations increased substantially over time. In 2014, 82% of
patients had at least one of the following tests: NP (8%), an ECG (37%), an echocardiogram
(51%), or specialist assessment (28%), compared with 37% in 2002 (RR 2.24 [2.15, 2.34])
(Table 2).
Treatment initiation and dosages over time. Amongst patients with a diagnosis of heart
failure recorded in primary care, reduced ejection fraction, and no contraindications or intol-
erances, prescriptions of essential drugs within three months of incident diagnosis differed by
drug class. In 2014, prescription rates were high for ACE-Is or ARBs (80%) and beta blockers
(72%) but lower for MRAs (28%) (Table 2).
Average daily doses prescribed over the 12 months following diagnosis remained below the
recommended targets doses throughout the study period (2014 values: 42% for ACE-Is or
ARBs, 29% for beta blockers, 22% for MRAs). When taken combined, the overall dose of beta
blockers and ACE-Is/ARBs prescribed to patients changed little over time (adjusted difference
from 2002 to 2014: +6% [+2%, +10%]), although patterns differed by individual drug classes
and declined for ACE-Is or ARBs (adjusted difference from 2002 to 2014: −7% [−13%, −2%])
(Table 2).
Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure
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Fig 2 provides a graphical overview of care delivery indicators and diverging temporal
trends.






(n = 11,578, 12%)
Inpatient (HF Secondary
Cause)
(n = 40,789, 44%)
Outpatient (Specialist or
Primary Care)
(n = 40,707, 44%)
Age [years], mean (SD) 76.7 (12.6) 78.1 (12.6) 77.6 (12.4) 75.4 (12.7)
Women, no. (%) 45,647 (49%) 6,054 (52%) 20,844 (51%) 18,749 (46%)
Ethnicity, no. (%)
White 56,011 (88%) 6,974 (88%) 25,259 (88%) 23,778 (87%)
Missing 29,122 (31%) 3,609 (31%) 12,132 (30%) 13,381 (33%)
Socioeconomic status, no. (%)
1 (least deprived) 18,371 (20%) 2,182 (19%) 7,889 (19%) 8,300 (20%)
2 20,073 (22%) 2,492 (21%) 8,600 (21%) 8,981 (22%)
3 20,052 (22%) 2,479 (21%) 8,697 (21%) 8,876 (22%)
4 18,308 (20%) 2,307 (20%) 8,122 (20%) 7,879 (19%)
5 (most deprived) 16,270 (17%) 2,118 (18%) 7,481 (18%) 6,671 (16%)
Systolic blood pressure
Mean (SD) [mmHg] 133 (21) 133 (21) 132 (20) 133 (201)
Missing, no. (%) 5,195 (6%) 654 (6%) 2,656 (7%) 1,885 (5%)
Diastolic blood pressure
Mean (SD) [mmHg] 74 (12) 74 (12) 74 (11) 75 (12)
Missing, no. (%) 5,195 (6%) 654 (6%) 2,656 (7%) 1,885 (5%)
BMI category, no. (%)
Underweight 2,193 (4%) 284 (4%) 1,107 (5%) 802 (3%)
Normal 17,381 (31%) 2,164 (33%) 7,657 (32%) 7,560 (30%)
Overweight 18,786 (34%) 2,067 (31%) 7,818 (33%) 8,901 (35%)
Obese 17,644 (31%) 2,139 (32%) 7,162 (30%) 8,343 (33%)
Missing 37,070 (40%) 4,924 (43%) 17,045 (42%) 15,101 (37%)
Smoking, no. (%)
No 29,551 (41%) 3,787 (44%) 12,647 (40%) 13,117 (41%)
Ex 32,572 (45%) 3,683 (43%) 14,299 (46%) 14,590 (46%)
Yes 9,596 (13%) 1,082 (13%) 4,360 (14%) 4,154 (13%)
Missing 21,355 (23%) 3,026 (26%) 9,483 (23%) 8,846 (22%)
Comorbidities
Atrial fibrillation, no. (%) 36,950 (40%) 5,199 (45%) 17,325 (42%) 14,426 (35%)
Chronic kidney disease, no. (%) 22,762 (24%) 3,233 (28%) 11,336 (28%) 8,193 (20%)
Chronic obstructive pulmonary disease, no. (%) 17,896 (19%) 2,113 (18%) 9,276 (23%) 6,507 (16%)
Diabetes, no. (%) 20,531 (22%) 2,952 (25%) 9,412 (23%) 8,167 (20%)
Dyslipidaemia, no. (%) 25,958 (28%) 3,281 (28%) 12,524 (31%) 10,153 (25%)
Hypertension, no. (%) 62,419 (67%) 8,226 (71%) 28,776 (71%) 25,417 (62%)
Ischaemic heart disease, no. (%) 45,584 (49%) 5,804 (50%) 22,247 (55%) 17,533 (43%)
Osteoarthritis, no. (%) 40,176 (43%) 5,029 (43%) 18,227 (45%) 16,920 (42%)
3 or more comorbidities, no. (%) 73,610 (79%) 9,567 (83%) 34,904 (86%) 29,139 (72%)
Number and percentage of records with missing data are displayed for variables with missing entries. Category percentages refer to complete cases. Socioeconomic
status refers to IMD 2015 quintile, with 1 referring to the most affluent and 5 to the most deprived quintile. Number of comorbidities refers to any of the 17 conditions
investigated (see Methods). Abbreviations: BMI, body-mass index; HF, heart failure; IMD, Index of Multiple Deprivation.
https://doi.org/10.1371/journal.pmed.1002805.t001
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Treatment titration patterns before and after incident diagnosis
Prescription rates of the investigated drug classes in the three months preceding heart failure
diagnosis were substantial (44% for ACE-Is or ARBs, 22% for beta blockers, and 3% for
MRAs) and were largely related to an existing diagnosis of hypertension (RR for the prescrip-
tion of at least one treatment class in patients with hypertension versus no hypertension: 2.07
[1.96, 2.18]).
Dose increments happened largely in the first 30 days following diagnosis, with no evidence
of consistent increments thereafter (Fig 3). Because estimation of average doses across the
whole population could potentially mask changes in dosing at the individual patient level, we
further investigated changes to treatment dose by categories of ‘no change’, ‘increase’, or
‘decrease’ at fixed time intervals of 2 and 12 months after diagnosis. This showed that even in
more recent years (2012–2014), for about half of the patients (52%), there was no change in
dosage of ACE-Is or ARBs between month 2 and month 12 after diagnosis. The treatment
dose decreased in 19% and increased in 29% of patients. At the end of one year, 27% of patients
received no ACE-I or ARB treatment, and another 36% were on<50% of the guideline-
Table 2. Temporal trends in essential care indicators following incident HF by year of diagnosis.
Denominator Cohort (n) 2002–2014 2002 2014 p for Trend
Diagnosis Care Setting All patients with HF (93,074) n (%) n (%) n (%) RR [95% CI]
Inpatient (HF primary cause) 11,578 (12%) 912 (12%) 740 (12%) 0.94 [0.86, 1.03] 0.02
Inpatient (HF secondary cause) 40,789 (44%) 2,277 (31%) 3,242 (52%) 1.67 [1.6, 1.74] <0.001
Outpatient (specialist or primary care) 40,707 (44%) 4,120 (56%) 2,260 (36%) 0.64 [0.62, 0.67] <0.001
Posthospitalisation Follow- Up n (%) n (%) n (%) RR [95% CI]
All inpatients Inpatients, discharged alive (40,856) 6,807 (17%) 489 (20%) 459 (14%) 0.73 [0.65, 0.82] <0.001
Inpatient (HF primary cause) Primary inpatients, discharged alive (9,195) 2,854 (31%) 228 (32%) 174 (29%) 0.95 [0.80, 1.12] 0.209
Inpatient (HF secondary cause) Secondary inpatients, discharged alive (31,661) 3,953 (12%) 261 (15%) 285 (11%) 0.73 [0.62, 0.85] <0.001
Diagnostic Investigations Patients diagnosed or followed up in primary care (47,925) n (%) n (%) n (%) RR [95% CI]
Echocardiogram 24,649 (51%) 796 (17%) 1,693 (62%) 3.56 [3.36, 3.78] <0.001
ECG 17,928 (37%) 995 (21%) 1,090 (40%) 1.83 [1.71, 1.96] <0.001
NP test 4,177 (9%) NA 616 (23%) NA NA
Specialist assessment 14,046 (29%) 563 (12%) 847 (31%) 2.5 [2.27, 2.75] <0.001
At least 1 diagnostic investigation 33,660 (70%) 1,683 (37%) 2,248 (82%) 2.24 [2.15, 2.34] <0.001
Treatment Initiation Patients diagnosed or followed up in primary care, reduced ejection
fraction (11,040), and no drug-specific contraindication
n (%) n (%) n (%) RR [95% CI]
ACE-I/ARB 9,920 7,748 (78%) 285 (75%) 586 (80%) 1.06 [0.99, 1.13] <0.001
Beta blocker 8,430 4,661 (55%) 72 (22%) 490 (72%) 3.27 [2.65, 4.03] <0.001
MRA 10,896 1,999 (18%) 59 (14%) 207 (26%) 1.88 [1.45, 2.44] <0.001
Beta blocker and ACE-I/ARB 7,768 3,759 (48%) 56 (18%) 403 (63%) 3.48 [2.72, 4.43] <0.001
Treatment Dose Patients diagnosed or followed up in primary care, reduced ejection
fraction (11,040) and no drug-specific contraindication
mean (SD) mean (SD) mean (SD) Adjusted
difference [95% CI]
ACE-I/ARB 9,920 48% (45%) 50% (44%) 42% (41%) −7% [−13%, −2%] <0.001
Beta blocker 8,430 25% (30%) 11% (22%) 29% (32%) 19% [15%, 22%] <0.001
MRA 10,896 18% (39%) 16% (36%) 20% (37%) 5% [1, 9%] <0.001
Beta blocker and ACE-I/ARB 7,768 36% (30%) 30% (26%) 35% (29%) 6% [2%, 10%] <0.001
RRs or adjusted differences and 95% CIs comparing 2014 to 2002, adjusting for year of diagnosis, age, sex, socioeconomic status, and region. Primary care follow-up
refers to the documentation of HF in primary care records during a follow-up consultation within 12 months of an incident diagnosis in hospital. Diagnostic
investigations refer to investigations referred for within ±6 months of incident heart failure. Treatment initiation refers to the issue of at least 1 prescription within 3
months of incident heart failure. Treatment dose presents the average daily dose prescribed in the first 12 months following incident heart failure as percent of
guideline-recommended target dose. Abbreviations: ACE-I, angiotensin-converting–enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval;
ECG, electrocardiogram; HF, heart failure; MRA, mineralocorticoid receptor antagonist; NA, not applicable; NP, natriuretic peptide; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002805.t002
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recommended dose (Fig 4A). The patterns of changes were similar for beta blockers, for which
a year after diagnosis, 30% did not receive this treatment (Fig 4B). Although overall doses
changed over time, patterns of up-titration remained similar across time periods (S1 Fig).
To allow comparison with clinical trials and cross-sectional observational studies, we fur-
ther report supplementary analyses on maximal prescribed doses as well as dosages amongst
patients initiated on therapy (S7 Table).
Stratified analyses by age, sex, and socioeconomic status. We observed variations in
care by age, sex, and socioeconomic status (Fig 5).
Women were less commonly diagnosed in outpatient settings and had lower rates of pri-
mary care follow-up, fewer diagnostic investigations, less treatment initiation, and lower treat-
ment doses than their male counterparts of similar age, socioeconomic status, and region.
Older patients (aged�75 years) exhibited similar and significant differences compared
with their middle-aged counterparts (55 to 64 years old). The very young (<45 years) patients,
particularly young women, had lower rates of diagnostic investigations across all four test
types compared with the 55 to 64 years age group (S8 Table).
Amongst patients managed by their general practitioner, no socioeconomic disparities
were apparent with regard to prescriptions of treatment or dose of treatment. However,
deprived patients had lower rates of diagnosis in outpatient settings than their more affluent
counterparts and hence were overall less likely to receive primary care follow-up.
Fig 2. Care delivery indicators following incident heart failure, by year of diagnosis, in CPRD from 2002 to 2014. Results are presented as fitted local polynomial
regression over yearly averages and 95% CIs (dashed lines). ACE-I, angiotensin-converting–enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval;
CPRD, Clinical Practice Research Datalink; ECG, electrocardiogram; NP, natriuretic peptide.
https://doi.org/10.1371/journal.pmed.1002805.g002
Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002805 May 21, 2019 10 / 18
Disparities remained apparent, although attenuated after adjusting for differences in fol-
low-up times, 30-day mortality, and baseline comorbidities (S2 Text), with the exception of
differences in primary care follow-up in patients aged�75 years.
Discussion
This large-scale, population-based study provides important information on contemporary
care of heart failure patients in routine clinical practice and insights into its variation over time
by age, sex, and socioeconomic status. Our study confirms previous reports of high rates of
guideline-indicated diagnostic investigations and treatment initiation in Western countries
(S1 Table). However, further investigation of care across the continuum of primary and sec-
ondary services and from the prediagnosis stage to several months after incident diagnosis
revealed important shortcomings in the management of patients. First, rates of outpatient
diagnoses and follow-up in primary care after hospital discharge are low and have been declin-
ing over time. Second, doses of key medicines remain far below those recommended in guide-
lines in all groups of patients and for all three drug classes investigated, even a year after
diagnosis. Finally, deficiencies in care were more common in women, older people, and, to
some extent, socioeconomically deprived individuals.
Indeed, we found that rates of outpatient diagnoses have been declining whilst more
patients are being diagnosed acutely in hospital. Relatedly, we found that only 17% of patients
who were first diagnosed in hospital were subsequently followed up with a heart failure
Fig 3. Average daily dose of guideline-recommended treatments prescribed around the time of incident heart failure in patients diagnosed
from 2012–2014. Average daily dose prescribed to patients with heart failure and reduced ejection fraction without drug-specific contraindications
or intolerances, from 3 months prior up to 12 months following incident heart failure, in patients diagnosed between 2012 and 2014, smoothed with
local polynomial regression. Average daily dose is expressed as a percentage of the guideline-recommended target dose. ACE-I, angiotensin-
converting–enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
https://doi.org/10.1371/journal.pmed.1002805.g003
Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002805 May 21, 2019 11 / 18
diagnosis in primary care, and this rate has also been declining, in particular when heart failure
was not the primary discharge diagnosis. The reasons for the declining trends in diagnosis and
follow-up of heart failure patients outside the acute hospital setting are not entirely clear and
seem rather surprising when put in the context of the growing access to diagnostic services
such as blood BNP outside hospitals and the reported shift in diagnosis from hospitals to out-
patient settings elsewhere [21]. Our findings suggest that out-of-hospital screening and follow-
up are suboptimal, and this could, at least partly, be due to poor record-keeping in primary
care and inadequate information exchange between hospitals and primary care. It might also
be that the national primary care reporting and incentive scheme [22] itself paradoxically con-
tributed to these trends, with general practitioners, for instance, using free text descriptions to
record patients’ problems rather than formally recording heart failure as a diagnosis. Such
practices that avoid registering certain patients who will not achieve management recommen-
dations to achieve higher overall adherence rates have been reported for other chronic condi-
tions, such as depression [23,24]. Recent investments in specialist heart failure clinics and
nurse-led services [25] might also have contributed to the observed patterns by creating artifi-
cially low primary care diagnosis and follow-up rates. Support for this comes from our sensi-
tivity analyses, which indicate that some patients receive heart failure medicines in primary
care despite no formal documentation of heart failure (S1 Text).
However, irrespective of the underlying reasons, the declining rates of heart failure record-
ing in primary care are likely to have important consequences for patient care as well as
research. The UK healthcare system relies on primary care as the cornerstone of chronic dis-
ease management. In such systems, general practitioners take a central role in screening, coor-
dination, and continuous management of common conditions such as heart failure. Even
Fig 4. Drug dose trajectory of (A) ACE-I or ARB dose and (B) beta blocker, prescribed around the time of
incident heart failure, in patients diagnosed from 2012–2014. Drug dose trajectory prescribed to patients with heart
failure and reduced ejection fraction without contraindications or intolerances, in patients with incident heart failure
between 2012 and 2014. ‘Month –1’ presents the average daily dose prescribed in the 30 days preceding incident heart
failure. ‘Month 2’ presents the average daily dose prescribed in the second month (days 30 to 60) following incident
heart failure. ‘Month 12’ presents the average daily dose prescribed in the twelfth month (days 335 to 365) following
incident heart failure. ACE-I, angiotensin-converting–enzyme inhibitor; ARB, angiotensin receptor blocker.
https://doi.org/10.1371/journal.pmed.1002805.g004
Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure




























































































































































































































































































































































































































































































































































































































































































































Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002805 May 21, 2019 13 / 18
where specialist clinics and nurse-led community services exist, general practitioners remain
responsible for medication prescriptions and the coordination of specialty care. Accurate dis-
ease recording in primary care is therefore particularly important for this patient population
with a high number of both cardiovascular and noncardiovascular comorbidities [15], and
gaps in healthcare records are likely to have effects on subsequent monitoring and manage-
ment of patients. This under-registration might also explain why some previous analyses con-
cluded that the incidence of heart failure is declining in the UK [26] (which was refuted in
subsequent studies that used linked records to capture cases across primary and secondary
care) [15].
The increase in the proportion of patients initiated on evidence-based therapy for heart fail-
ure in recent years is important and encouraging because prescription of treatment, even at
low dose, is an essential component of heart failure management. Yet gaps remain, particularly
for beta blockers and MRAs. Whilst comparison across studies is difficult because of varying
inclusion criteria and time points at which treatment plans are evaluated, rates appear some-
what lower than those reported in other countries (S1 Table), and underuse of these therapies
are likely to be associated with significant loss of life, both quantity and quality [27]. Moreover,
the average dose received per patient remained far below the guideline-recommended doses,
and despite increasing numbers of patients initiated on therapy, the overall dose prescribed
did not change substantially from 2002 to 2014. Titration was largely restricted to the 30-day
period after incident diagnosis, yet landmark clinical trials have established the value of opti-
mal drug dosages in conferring clinical benefits [28–30]. Whilst it may not be possible for
every patient to achieve guideline-recommended doses, the rates reported by our study remain
below rates achieved through community-based interventions or in clinical trials [31]. Our
findings hence question whether current efforts in community heart failure services suffi-
ciently address the long-term needs of patients with heart failure. In addition, they show that
the current UK focus on monitoring diagnostic tests and treatment initiation might distract
attention away from medication maintenance and titration as a measure of quality of care.
Our study further shows that the management of women, older people, and deprived indi-
viduals was even less satisfactory. For example, all were more likely to be first diagnosed during
a hospital admission. This may suggest that, in these patients, early signs and symptoms have
not been appropriately recognised in nonacute healthcare settings. Alternatively, this may be
related to patient preferences to seek care in hospital or, for deprived populations, to more dif-
ficult access to outpatient consultations [32]. Correcting such disparities is an important chal-
lenge for a system that intends to offer equality of access to and quality of care.
Healthcare reporting efforts play an important role in improving quality of care. Our study
presents changes in the delivery of care alongside the implementation of landmark quality
improvement initiatives, in particular the QOF, a reporting and incentives scheme for primary
care introduced in 2004 [22], and the NHFA, a reporting programme for secondary care intro-
duced in 2007 [11]. These schemes represent the primary source of quality of care data in the
UK so far and report a very positive picture of heart failure management. For example, both
report very high rates of diagnostic investigations (91%–95%) [12,13] and treatment initiation
(85%–99% for ACE-Is or ARBs) [12,13] that, given the small differences in variable definitions,
are comparable to the present findings. However, the investigation of care across the contin-
uum of primary and secondary services reveals important shortcomings in the management of
patients that analyses confined to individual clinical settings are unable to identify. When
reflecting specifically on the financial incentives programme, which applies to primary care, it
appears that its design insufficiently addresses patients’ long-term care needs. The scheme
incentivises general practitioners to follow evidence-based care practices and monitors over
100 indicators across a range of conditions. For heart failure, the scheme monitors referral for
Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002805 May 21, 2019 14 / 18
diagnostic investigations and yearly prescriptions of both beta blockers and ACE-Is or ARBs,
with financial rewards only for primary care practices that achieve set target rates. Our findings
reveal that incentivised indicators have improved over time but show no or negative changes
in associated outcomes. Perhaps most importantly, they reveal possible unintended conse-
quences in the fact that following the introduction of the programme, recording of diagnoses
in primary care declined considerably, leading to a large and growing number of patients for
whom continuous monitoring and management remains uncertain.
A major strength of this study is the use of a large population-based cohort of patients,
which allows a sufficient number of cases in each age, sex, and socioeconomic category for
subpopulation analyses and increases the generalisability of findings compared with surveys
enrolling more selected participants. Moreover, longitudinal data from electronic health rec-
ords provide a unique opportunity to follow patients over time in different care settings and
hence to address the limitations of selected single-setting and single-time–point indicators
used in previous studies. One of the key limitations of our study was the incomplete clinical
information contained in the available electronic health records. In particular, left ventricular
ejection fraction values were not available. Hence, we could only characterise the type of heart
failure in a subset of patients for whom the diagnostic code made a clear reference to reduced
ejection fraction. Whilst this subset of patients is likely to underestimate the true prevalence of
reduced ejection fraction in the community, its high specificity ensures the selection of
patients is appropriate for our analyses. Moreover, secondary care records did not provide
access to diagnostic investigations, procedures (such as device implantations), discharge pre-
scriptions or referrals, or outpatient consultations, so some analyses had to be restricted to pri-
mary care data. Finally, reliable information about patients’ symptoms was not available and
limited our ability to investigate precise indications for certain therapies, such as MRAs.
Our findings have important implications for health services policies. The increased uptake
of guideline-recommended diagnostic tests and treatment initiation amongst patients seen in
primary care suggests that early management of these patients has improved, probably because
of a combination of physician awareness, clinical guidelines, and financial incentives. How-
ever, the limited changes to medication dosages, the disparities amongst subgroups of patients,
and the poor rates of primary care recording indicate that more efforts are needed. Quality
improvement efforts that remained confined within individual care settings have proven insuf-
ficient to identify important care gaps and to address challenges of this chronic condition with
effective but complex treatment. Further improvements are likely to require a broader perspec-
tive to health services design to support appropriate care at every level of the patient journey.
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